We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A change in story

3 March 2005 By Robert Cyran

But the damage is done. The public s poor perception of the drug s safety means it will never deliver the growth investors once anticipated. Shares in the pharma group have rallied after US regulators allowed the group s controversial lead drug, Crestor, to stay on the market.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)